bioRxivPharmacology & Toxicology
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology
J. Inglese, P. Dranchak, E. Oliphant, B. Queme, L. Lamy, Y. Wang, R. Huang, M. Xia, D. Tao
Abstract
Quantitative high-throughput screening (qHTS) evaluates the pharmacology of drug and investigational agent libraries for potential therapeutic uses, toxicological risk assessment, and increasingly for academic chemical tool discovery. Phenotypic HTS assays aim to interrogate molecular pathways and networks, often relying on cell culture systems, historically with less emphasis on multicellular organisms. C. elegans has served as a powerful eukaryotic model organism for human biology and disease by virtue of genetic conservation and experimental tractability. Here we describe a paradigm to enable C. elegans in qHTS using 384-well microtiter plate laser scanning cytometry. GFP-expressing organisms are used to reveal phenotype-modifying structure-activity relationships to guide subsequent life stages and proteomic analysis. E. coli bacterial ghosts, a non-replicating nutrient source, allow compound exposures over 7-days spanning two life cycles to mitigate complications from bacterial overgrowth. We demonstrate the method with a library composed of anti-infective agents, or molecules of general toxicological concern. Each was tested in 7-point titration to assess the feasibility of nematode-based in vivo qHTS, and examples of follow-up strategies were provided to study organism-based chemotype selectivity and subsequent network perturbations having a physiological impact. We anticipate a broader application of this qHTS-coupled proteomics approach will enable the analysis of C. elegans orthologous transgenic phenotypes of human pathologies to facilitate drug and probe profiling from high-impact chemical libraries for a range of therapeutic indications and study of potential toxicological signatures. Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=159 SRC="FIGDIR/small/505462v1_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@7ef320org.highwire.dtl.DTLVardef@8bc35corg.highwire.dtl.DTLVardef@1c6f446org.highwire.dtl.DTLVardef@cf56f1_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: C. elegans
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- qHTSWaterfall: 3-dimensional visualization software for quantitative high-throughput screening (qHTS) data
Bryan Queme, John C. Braisted, … James Inglese·Journal of CheminformaticsPeer-reviewed·Mar 31, 2023
- An automated high-throughput system for phenotypic screening of chemical libraries on C. elegans and parasitic nematodes
F. A. Partridge, A. E. Brown, … D. B. Sattelle·bioRxiv·Sep 11, 2017
- Unveiling mode of action of anthelmintics in Caenorhabditis elegans with SydLab™, an on-a-chip automated and high-content screening system.
Thomas B. Duguet, Coralie Belgrano, … Lucien Rufener·bioRxiv·May 15, 2025
- Screening and characterization of 133 physiologically-relevant environmental chemicals for reproductive toxicity
G. Ulaganathan, H. Jiang, … P. Allard·bioRxiv·Mar 22, 2024
- Behavioral fingerprints predict insecticide and anthelmintic mode of action
Adam McDermott-Rouse, Eleni Minga, … André EX Brown·Molecular Systems BiologyPeer-reviewed·May 1, 2021
- Discovery of anthelmintic small molecules in the Medicines for Malaria Ventures COVID and Global Health Priority Boxes using an infrared-based assay for Caenorhabditis elegans motility
C. Caffrey, L. Liu, Y. U. Sun·bioRxiv·Dec 9, 2023